(S)-2-amino-N-methyl-4-phenylbutanamide | 245487-53-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-N-methyl-4-phenylbutanamide
• 英文别名: (2S)-2-amino-N-methyl-4-phenylbutanamide
• CAS: 245487-53-0
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: XVBCPGOCLOUCLE-JTQLQIEISA-N

物化性质

• 沸点：
  388.9±42.0 °C(Predicted)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-N-methyl-4-phenylbutanamide 在 palladium on activated charcoal 氢气 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、294.18 kPa 条件下， 生成 (R)-N4-hydroxy-2-isobutyl-N1-((S)-1-(methylamino)-1-oxo-4-phenylbutan-2-yl)succinamide
  参考文献：
  名称：

  Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors

  摘要：

  The synthesis and biological evaluation of orally active inhibitors of matrix metalloproteinase are reported. Modifications of the P2' position and the a-substituent of hydroxamic acid derivatives were carried out, and revealed that the P2' substituent influenced the MMP inhibitory activities in vitro and in plasma after oral administration. The hydroxamates with phenylglycine at the P2' position were absorbed well orally. Compound 15e, which exhibited the longest duration of inhibitory activity in plasma after oral administration among the phenylglycine derivatives (5a-5d, 15a, 15c, 15e), was evaluated in a rat adjuvant arthritis model. A reduction in hind foot pad swelling and improvements of some inflammatory parameters were demonstrated when the compound was administered orally. These results indicate the potential of MMP inhibitors for rheumatoid arthritis. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00028-x
• 作为产物：
  描述：

  (alphaS)-alpha-氨基苯丁酸甲酯盐酸盐 在 甲胺 作用下， 以 乙醇 为溶剂， 以83%的产率得到(S)-2-amino-N-methyl-4-phenylbutanamide
  参考文献：
  名称：

  WO2008/104756

  摘要：

  公开号：

文献信息

• [EN] 4 - (5 - ISOXAZOLYL OR 5 - PYRRAZOLYL -1,2,4- OXADIAZOL - 3 - YL) -MANDELIC ACID AMIDES AS SPHINGOSIN- 1 - PHOSPHATE 1 RRECEPTOR AGONISTS<br/>[FR] AMIDES D'ACIDE 4-(5-ISOXAZOLYL OU 5-PYRAZOLYL-1,2,4-OXADIAZOL-3-YL)-MANDÉLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE DE TYPE 1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011133734A1

  公开（公告）日：2011-10-27

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R1 is phenyl substituted with zero to 3 substituents; and R1, R2, R3, R4, R5, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物或其立体异构体、盐或前药，其中：Q是，或者R1是苯基，其上取代基为零至3个；而R1、R2、R3、R4、R5和G在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• Substituted Dihydroisoquinolinones by Iodide-Promoted Cyclocarbonylation of Aromatic α-Amino Acids
  作者：Mostafa M. Amer、Ana C. Carrasco、Daniel J. Leonard、John W. Ward、Jonathan Clayden

  DOI：10.1021/acs.orglett.8b03551

  日期：2018.12.21

  of aromatic α-amino acids, on treatment with phosgene and potassium iodide, undergo a mild Bischler–Napieralski-style cyclocarbonylation reaction that generates a tricyclic lactam by insertion of a C═O group between amino acid nitrogen and the ortho position of the aryl substituent. Regio- and diastereoselective functionalization of the lactam generates a library of substituted dihydroisoquinolinones

  一系列芳香族 α-氨基酸的咪唑啉酮衍生物在用光气和碘化钾处理后，会发生温和的 Bischler-Napieralski 式环羰基化反应，通过在氨基酸氮和邻位之间插入 C=O 基团生成三环内酰胺。芳基取代基的位置。内酰胺的区域选择性和非对映选择性功能化产生了取代的二氢异喹啉酮及其对映体富集形式的同源物库。
• Asymmetric and Geometry‐Selective α‐Alkenylation of α‐Amino Acids
  作者：Hossay Abas、Josep Mas‐Roselló、Mostafa Mahmoud Amer、Derek J. Durand、Robin R. Groleau、Natalie Fey、Jonathan Clayden

  DOI：10.1002/anie.201813984

  日期：2019.2.18

  Both E‐ and Z‐N′‐alkenyl urea derivatives of imidazolidinones may be formed selectively from enantiopure α‐amino acids. Generation of their enolate derivatives in the presence of K+ and [18]crown‐6 induces intramolecular migration of the alkenyl group from N′ to Cα with retention of double bond geometry. DFT calculations indicate a partially concerted substitution mechanism. Hydrolysis of the enantiopure

  既ë -和ž - ñ咪唑啉酮类的“链烯基脲衍生物可以选择性地从对映体纯α-氨基酸形成。在存在K +和[18] crown-6的情况下生成其烯醇化物衍生物会导致烯基从N'到Cα的分子内迁移，并保留了双键的几何形状。DFT计算表明部分协调的替代机制。对映体纯产物在酸性条件下的水解揭示了具有绝对立体构型和双键几何构型的立体发散控制的季α-烯基氨基酸。
• Aromatic Interactions in Organocatalyst Design: Augmenting Selectivity Reversal in Iminium Ion Activation
  作者：Mareike C. Holland、Jan Benedikt Metternich、Constantin Daniliuc、W. Bernd Schweizer、Ryan Gilmour

  DOI：10.1002/chem.201500270

  日期：2015.7.6

  that intermolecular aromatic (CH–π and cation–π) interactions between the incipient iminium cation and the indole ring system is key to rationalising selectivity reversal. This is absent in the N‐methylpyrrole alkylation, thus forming the basis of two competing enantio‐induction pathways. A simple L‐valine catalyst has been developed that significantly augments this interaction.

  用N-甲基吡咯代替N仲胺催化的Friedel-Crafts反应中的亚甲基吲哚会引起对映选择性的奇怪侵蚀。在极端情况下，这种对底物的依赖性可能导致对映体诱导的反转。实际上，这些紧密相似的转化需要两种结构上不同的催化剂以获得可比较的选择性。本文公开了集中的分子编辑研究，以阐明造成这种差异的结构特征，从而鉴定铅催化剂结构以进一步利用这种选择性逆转。有效进行催化剂再工程的关键是描述以构象形式表现出来的非共价相互作用。本文中，我们公开了初步验证，即初始亚胺阳离子与吲哚环系统之间的分子间芳香族（CH-π和阳离子-π）相互作用是合理化选择性逆转的关键。这是不存在的N-甲基吡咯烷基化，因此形成了两个相互竞争的对映体诱导途径的基础。已经开发出一种简单的L-缬氨酸催化剂，可显着增强这种相互作用。
• Novel method of treatment of inflammatory skin conditions
  申请人：Chandler Rupert Stephen

  公开号：US20070049518A1

  公开（公告）日：2007-03-01

  There is provided, inter alia, a method for the treatment or prevention of an inflammatory skin condition which is characterised by colonisation with Staphylococcus aureus , comprising the topical administration of an aureolysin inhibitor.

  提供了一种治疗或预防由金黄色葡萄球菌定植引起的炎症性皮肤病的方法，包括局部施用一种金黄色葡萄球菌溶素抑制剂。